The AAV9-packaged RfxCas13d targeting mutant SOD1 reduced 50% of the expression of SOD1 in the ALS spinal cord, followed by functional improvement of neuromuscular disorders as well as decrease in muscle atrophy [124]. Here, SOD1 is linked to amyotrophic lateral sclerosis.